{
  "$schema": "folio-library-document/v1",
  "id": "10665-360861",
  "title": "Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance: technical brief",
  "variant": "pdf",
  "pages": 46,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Acknowledgements",
      "number": null,
      "page": 5,
      "pageLabel": "iv",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-acknowledgements"
    },
    {
      "level": 1,
      "title": "Abbreviations",
      "number": null,
      "page": 7,
      "pageLabel": "vi",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-abbreviations"
    },
    {
      "level": 1,
      "title": "Overview",
      "number": null,
      "page": 8,
      "pageLabel": "vii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-overview"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": null,
      "page": 10,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-introduction"
    },
    {
      "level": 2,
      "title": "Background",
      "number": null,
      "page": 10,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-background"
    },
    {
      "level": 2,
      "title": "Target audience and scope",
      "number": null,
      "page": 11,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-target-audience-and-scope"
    },
    {
      "level": 2,
      "title": "Guiding principle and methodology",
      "number": null,
      "page": 11,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-guiding-principle-and-methodology"
    },
    {
      "level": 1,
      "title": "Starting, using and stopping oral PrEP",
      "number": null,
      "page": 12,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-starting-using-and-stopping-oral-prep"
    },
    {
      "level": 2,
      "title": "Oral event-driven PrEP (ED-PrEP)",
      "number": null,
      "page": 12,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-oral-event-driven-prep-ed-prep"
    },
    {
      "level": 2,
      "title": "Starting and stopping oral PrEP",
      "number": null,
      "page": 12,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-starting-and-stopping-oral-prep"
    },
    {
      "level": 2,
      "title": "Rationale",
      "number": null,
      "page": 14,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-rationale"
    },
    {
      "level": 1,
      "title": "PrEP and hepatitis B and C",
      "number": null,
      "page": 15,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-prep-and-hepatitis-b-and-c"
    },
    {
      "level": 2,
      "title": "Hepatitis B virus",
      "number": null,
      "page": 15,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-hepatitis-b-virus"
    },
    {
      "level": 2,
      "title": "Hepatitis C virus",
      "number": null,
      "page": 16,
      "pageLabel": "7",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-hepatitis-c-virus"
    },
    {
      "level": 2,
      "title": "Rationale",
      "number": null,
      "page": 17,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-rationale"
    },
    {
      "level": 1,
      "title": "PrEP and kidney function",
      "number": null,
      "page": 18,
      "pageLabel": "9",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-prep-and-kidney-function"
    },
    {
      "level": 2,
      "title": "Rationale",
      "number": null,
      "page": 20,
      "pageLabel": "11",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-rationale"
    },
    {
      "level": 1,
      "title": "HIV self-testing (HIVST) for PrEP",
      "number": null,
      "page": 21,
      "pageLabel": "12",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-hiv-self-testing-hivst-for-prep"
    },
    {
      "level": 2,
      "title": "What is HIVST?",
      "number": null,
      "page": 21,
      "pageLabel": "12",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-what-is-hivst"
    },
    {
      "level": 2,
      "title": "HIVST and PrEP",
      "number": null,
      "page": 21,
      "pageLabel": "12",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-hivst-and-prep"
    },
    {
      "level": 2,
      "title": "Rationale",
      "number": null,
      "page": 23,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-020-rationale"
    },
    {
      "level": 1,
      "title": "Differentiated PrEP service delivery: When, where, who and what to deliver",
      "number": null,
      "page": 24,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-differentiated-prep-service-delivery-when-where"
    },
    {
      "level": 2,
      "title": "Building blocks of differentiated PrEP service delivery",
      "number": null,
      "page": 24,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-building-blocks-of-differentiated-prep-service-d"
    },
    {
      "level": 2,
      "title": "Where to deliver PrEP",
      "number": null,
      "page": 25,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-023-where-to-deliver-prep"
    },
    {
      "level": 2,
      "title": "PrEP in fixed and mobile community settings",
      "number": null,
      "page": 27,
      "pageLabel": "18",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-024-prep-in-fixed-and-mobile-community-settings"
    },
    {
      "level": 2,
      "title": "Telehealth for PrEP",
      "number": null,
      "page": 29,
      "pageLabel": "20",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-025-telehealth-for-prep"
    },
    {
      "level": 2,
      "title": "PrEP delivery in pharmacies",
      "number": null,
      "page": 31,
      "pageLabel": "22",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-026-prep-delivery-in-pharmacies"
    },
    {
      "level": 2,
      "title": "Who to deliver PrEP",
      "number": null,
      "page": 32,
      "pageLabel": "23",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-027-who-to-deliver-prep"
    },
    {
      "level": 2,
      "title": "When and what services to deliver",
      "number": null,
      "page": 33,
      "pageLabel": "24",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-028-when-and-what-services-to-deliver"
    },
    {
      "level": 2,
      "title": "Research gaps",
      "number": null,
      "page": 35,
      "pageLabel": "26",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-029-research-gaps"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 36,
      "pageLabel": "27",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-030-references"
    },
    {
      "level": 1,
      "title": "Annex 1: Summary of mathematical modelling of HIVST for PrEP in Kenya",
      "number": null,
      "page": 42,
      "pageLabel": "33",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-031-annex-1-summary-of-mathematical-modelling-of-hiv"
    },
    {
      "level": 1,
      "title": "Annex 2: Background and methods on the global PrEP provider study",
      "number": null,
      "page": 43,
      "pageLabel": "34",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-032-annex-2-background-and-methods-on-the-global-pre"
    },
    {
      "level": 1,
      "title": "Annex 3: Summary of a review of PrEP services for people who inject drugs",
      "number": null,
      "page": 45,
      "pageLabel": "36",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-033-annex-3-summary-of-a-review-of-prep-services-for"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 5,
      "labelStart": "C1",
      "labelEnd": "iv",
      "words": 747,
      "summary": {
        "text": "The cover, title and copyright pages of the 2022 WHO technical brief on differentiated and simplified pre-exposure prophylaxis (PrEP) for HIV prevention, with ISBNs and licence terms. It gives the suggested citation and disclaimers. A table of contents lists sections on delivering PrEP, research gaps and annexes on HIV self-testing modelling in Kenya, a global PrEP provider study and PrEP for people who inject drugs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "differentiated prep",
          "heading": false
        },
        {
          "term": "deliver prep",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "yoshi shimizu",
          "heading": false
        },
        {
          "term": "eric gauss",
          "heading": false
        },
        {
          "term": "prep service",
          "heading": false
        },
        {
          "term": "simplified pre-exposure",
          "heading": false
        },
        {
          "term": "pre-exposure prophylaxis",
          "heading": false
        }
      ],
      "extract": "Differentiated and simplified pre-exposure prophylaxis for HIV prevention Update to WHO implementation guidance TECHNICAL BRIEF Update to WHO implementation guidance TECHNICAL BRIEF Differentiated and simplified pre-exposure prophylaxis for HIV prevention Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance. Technical Brief ISBN 978-92-4-005369-4",
      "extractCut": true,
      "blocks": [
        "library/10665-360861/blocks/prose-sec-front-matter",
        "library/10665-360861/blocks/figure-img-p001-1",
        "library/10665-360861/blocks/figure-img-p001-2",
        "library/10665-360861/blocks/figure-img-p001-3",
        "library/10665-360861/blocks/figure-img-p001-4",
        "library/10665-360861/blocks/figure-img-p001-5",
        "library/10665-360861/blocks/figure-img-p001-6"
      ]
    },
    {
      "id": "sec-000-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 7,
      "labelStart": "iv",
      "labelEnd": "vi",
      "words": 772,
      "summary": {
        "text": "The acknowledgements of the technical brief on differentiated and simplified PrEP, listing external contributors from research institutions, programmes and organizations in many countries. It notes grant funding from Unitaid, the Bill & Melinda Gates Foundation and USAID.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hôpital saint-louis",
          "heading": false
        },
        {
          "term": "united kingdom",
          "heading": false
        },
        {
          "term": "hopkins university",
          "heading": false
        },
        {
          "term": "greater glasgow",
          "heading": false
        },
        {
          "term": "heather-marie schmidt",
          "heading": false
        },
        {
          "term": "usa",
          "heading": false
        },
        {
          "term": "nhs greater",
          "heading": false
        },
        {
          "term": "unaids regional",
          "heading": false
        }
      ],
      "extract": "External contributors WHO would like to thank the following external contributors to this brief who participated in technical consultations and provided and reviewed content: Chris Akolo (FHI 360, United States of America (USA)), Adam Akullian (Institute for Disease Modeling, USA), Pedro Henrique Amparo da Costa Leite (Fiocruz, Brazil), Lynsey Boyd (Sandyford Sexual Health Services, NHS Greater Glasgow & Clyde,",
      "extractCut": true
    },
    {
      "id": "sec-001-abbreviations",
      "number": null,
      "title": "Abbreviations",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 8,
      "labelStart": "vi",
      "labelEnd": "vii",
      "words": 80,
      "summary": {
        "text": "A list of abbreviations used in the PrEP technical brief, such as CAB-LA, ED-PrEP, HBsAg and TDF.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "glomerular filtration",
          "heading": false
        },
        {
          "term": "filtration rate",
          "heading": false
        },
        {
          "term": "hepatitis virus",
          "heading": false
        },
        {
          "term": "gfr",
          "heading": false
        }
      ],
      "extract": "ART antiretroviral therapy CAB-LA long-acting injectable cabotegravir DVR dapivirine vaginal ring ED-PrEP event-driven PrEP eGFR estimated glomerular filtration rate FTC emtricitabine GFR glomerular filtration rate HBsAg HBV surface antigen HBV hepatitis B virus HCV hepatitis C virus HIV human immunodeficiency virus HIVST HIV self-testing MMD multi-month dispensing NRTI nucleoside reverse transcriptase inhibitor PEP",
      "extractCut": true
    },
    {
      "id": "sec-002-overview",
      "number": null,
      "title": "Overview",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 10,
      "labelStart": "vii",
      "labelEnd": "1",
      "words": 858,
      "summary": {
        "text": "Gives an overview of the technical brief, which updates WHO guidance to support differentiated, simplified, demedicalized PrEP services in line with the 2022–2030 global health sector strategies. It lists key points on starting and stopping oral PrEP, including event-driven dosing for people assigned male at birth not taking estradiol-based hormones, and on hepatitis B and C testing. It also introduces the four building blocks of differentiated delivery: where, who, when and what.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "differentiated prep",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "hivst-supported prep",
          "heading": false
        },
        {
          "term": "prep initiation",
          "heading": false
        },
        {
          "term": "prep service",
          "heading": false
        },
        {
          "term": "prep delivery",
          "heading": false
        },
        {
          "term": "prep uptake",
          "heading": false
        },
        {
          "term": "kidney function",
          "heading": false
        }
      ],
      "extract": "What is this technical brief? This technical brief by the World Health Organization (WHO) updates and supplements previous WHO guidelines and guidance on pre-exposure prophylaxis (PrEP) for HIV prevention. The brief aims to support differentiated, simplified, demedicalized and comprehensive PrEP services. This can support PrEP uptake, persistence and effective use and assist efforts to achieve global goals set out",
      "extractCut": true
    },
    {
      "id": "sec-003-introduction",
      "number": null,
      "title": "Introduction",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 10,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-004-background",
      "number": null,
      "title": "Background",
      "level": 2,
      "pageStart": 10,
      "pageEnd": 11,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 663,
      "summary": {
        "text": "Explains what PrEP is and recalls that WHO's 2015 recommendation of TDF-based oral PrEP was cautious because experience was limited, whereas services have since been widely simplified, demedicalized and integrated. It states the brief's aim of supporting these trends, accelerated by COVID-19, towards the UN target of fewer than 370 000 new infections by 2025, and summarises WHO PrEP recommendations in a box.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "prep services",
          "heading": false
        },
        {
          "term": "hiv acquisition",
          "heading": false
        },
        {
          "term": "substantial risk",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "combination prevention",
          "heading": false
        },
        {
          "term": "prevention approaches",
          "heading": false
        },
        {
          "term": "prevention choice",
          "heading": false
        }
      ],
      "extract": "Pre-exposure prophylaxis (PrEP) for HIV prevention is the use of antiretroviral drugs by HIV-negative individuals to reduce the risk of acquisition of HIV. The World Health Organization (WHO) has recommended multiple PrEP options as part of combination prevention approaches (Box 1). When WHO recommended offering TDF-based oral PrEP to people at substantial risk for HIV in 2015 (Box 2), implementation of PrEP",
      "extractCut": true
    },
    {
      "id": "sec-005-target-audience-and-scope",
      "number": null,
      "title": "Target audience and scope",
      "level": 2,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 149,
      "summary": {
        "text": "Describes the brief's audience and scope: it supplements WHO consolidated HIV guidelines and the PrEP Implementation Tool, focusing on TDF-based oral PrEP while noting considerations for the dapivirine vaginal ring and long-acting cabotegravir.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "prep implementation",
          "heading": false
        },
        {
          "term": "prep products",
          "heading": false
        },
        {
          "term": "dvr",
          "heading": false
        },
        {
          "term": "cab-la",
          "heading": false
        }
      ],
      "extract": "This technical brief aims to support a range of stakeholders in planning and implementing PrEP services. It provides guidance on PrEP implementation and is meant to supplement and update guidance previously published in the WHO Consolidated HIV Guidelines (4) and the WHO PrEP Implementation Tool.3 The guidance in this document relates primarily to TDF-based oral PrEP (including TDF in combination with emtricitabine",
      "extractCut": true
    },
    {
      "id": "sec-006-guiding-principle-and-methodology",
      "number": null,
      "title": "Guiding principle and methodology",
      "level": 2,
      "pageStart": 11,
      "pageEnd": 12,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 375,
      "summary": {
        "text": "Describes the brief's people-centred, rights-based approach and how it was developed by a WHO core group with an expert working group, including management of declarations of interest. It also begins guidance that eligible people assigned male at birth may choose event-driven or daily oral PrEP, with a footnote defining transgender people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gender nonconforming",
          "heading": false
        },
        {
          "term": "oral ed-prep",
          "heading": false
        },
        {
          "term": "gender diverse",
          "heading": false
        },
        {
          "term": "external contributors",
          "heading": false
        },
        {
          "term": "external experts",
          "heading": false
        },
        {
          "term": "diverse people",
          "heading": false
        },
        {
          "term": "core group",
          "heading": false
        },
        {
          "term": "working group",
          "heading": false
        }
      ],
      "extract": "This technical brief follows a public health, human rights and people-centred approach to provide evidence-based guidance on PrEP service delivery. Such an approach puts the people and communities who could benefit from PrEP services at the centre of service delivery, adapting services to their preferences and needs while maximizing impact and health system efficiency. The development of this brief was led by a core",
      "extractCut": true
    },
    {
      "id": "sec-007-starting-using-and-stopping-oral-prep",
      "number": null,
      "title": "Starting, using and stopping oral PrEP",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 3,
      "summary": {
        "text": "A heading fragment for the section on starting, using and stopping oral PrEP.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "stopping oral PrEP",
      "extractCut": false
    },
    {
      "id": "sec-008-oral-event-driven-prep-ed-prep",
      "number": null,
      "title": "Oral event-driven PrEP (ED-PrEP)",
      "level": 2,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-009-starting-and-stopping-oral-prep",
      "number": null,
      "title": "Starting and stopping oral PrEP",
      "level": 2,
      "pageStart": 12,
      "pageEnd": 14,
      "labelStart": "3",
      "labelEnd": "5",
      "words": 773,
      "summary": {
        "text": "Sets out how to start and stop oral PrEP: people eligible for event-driven PrEP take a double loading dose 2–24 hours before sex and continue daily until two days after the last exposure. All other groups, including cisgender women and people who inject drugs, take seven daily doses before protection and stop seven days after the last exposure. A figure illustrates the dosing timelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "oral prep",
          "heading": true
        },
        {
          "term": "stopping oral",
          "heading": true
        },
        {
          "term": "oral ed-prep",
          "heading": false
        },
        {
          "term": "exogenous estradiol",
          "heading": false
        },
        {
          "term": "day until",
          "heading": false
        },
        {
          "term": "start prep",
          "heading": false
        },
        {
          "term": "stop prep",
          "heading": false
        },
        {
          "term": "sexual exposure",
          "heading": false
        }
      ],
      "extract": "To reduce the risk of HIV acquisition through sexual exposure, cisgender men and trans and gender diverse people assigned male at birth4 who are not taking exogenous estradiol-based hormones may be offered oral daily PrEP or ED-PrEP as options (Table 1 and Figure 1). Whether the intention is to use oral daily PrEP or ED-PrEP, people eligible for ED-PrEP can start and stop PrEP using the same strategy: • Start PrEP",
      "extractCut": true
    },
    {
      "id": "sec-010-rationale",
      "number": null,
      "title": "Rationale",
      "level": 2,
      "pageStart": 14,
      "pageEnd": 15,
      "labelStart": "5",
      "labelEnd": "6",
      "words": 612,
      "summary": {
        "text": "Explains the evidence that event-driven PrEP is as effective as daily PrEP for cisgender men who have sex with men and why it can be extended to all people assigned male at birth not taking estradiol-based hormones, regardless of sexual positioning. It notes insufficient evidence for other groups and compares lead-in and stopping times recommended in other guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ed-prep dosing",
          "heading": false
        },
        {
          "term": "insertive positioning",
          "heading": false
        },
        {
          "term": "cisgender men",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "estradiol-based hormones",
          "heading": false
        },
        {
          "term": "gender-affirming hormones",
          "heading": false
        },
        {
          "term": "assigned male",
          "heading": false
        },
        {
          "term": "anal sex",
          "heading": false
        }
      ],
      "extract": "Data from trials, open label extension studies and demonstration studies have shown that oral PrEP using the ED-PrEP dosing regimen is as effective in preventing HIV infection as daily PrEP in cisgender men who have sex with men (6–8). As a result, WHO recommended that an ED-PrEP regimen is safe and highly effective in reducing risk of HIV acquisition through receptive and/ or insertive sex between cisgender men and",
      "extractCut": true
    },
    {
      "id": "sec-011-prep-and-hepatitis-b-and-c",
      "number": null,
      "title": "PrEP and hepatitis B and C",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 245,
      "summary": {
        "text": "Gives a flowchart-style summary of hepatitis B management in PrEP services: vaccination for those testing HBsAg-negative and assessment for treatment for those positive. It explains that TDF-based PrEP also suppresses hepatitis B, notes the small risk of relapse after stopping and the need for monitoring.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "hbv treatment",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "tdf-based oral",
          "heading": false
        },
        {
          "term": "hbsag test",
          "heading": false
        },
        {
          "term": "suppress",
          "heading": false
        },
        {
          "term": "cirrhosis",
          "heading": false
        },
        {
          "term": "clinical evidence",
          "heading": false
        }
      ],
      "extract": "B and C ▶ HBsAg test is non-reactive: WHO recommends HBV vaccination for people at risk of acquiring HBV (25).5 ▶ HBsAg test is reactive: Further assessment for HBV treatment eligibility. • Eligibility for long-term therapy for HBV infection as per WHO guidance (26): – People with detectable HBsAg and clinical evidence of compensated or decompensated cirrhosis. – People older than 30 years with persistently abnormal",
      "extractCut": true
    },
    {
      "id": "sec-012-hepatitis-b-virus",
      "number": null,
      "title": "Hepatitis B virus",
      "level": 2,
      "pageStart": 15,
      "pageEnd": 16,
      "labelStart": "6",
      "labelEnd": "7",
      "words": 331,
      "summary": {
        "text": "Recommends testing PrEP users once for hepatitis B surface antigen, especially in highly endemic countries, while stressing that lack of testing must not delay PrEP. It notes that oral PrEP and the dapivirine ring are safe for people with hepatitis B or C and repeats the key points on hepatitis testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep initiation",
          "heading": false
        },
        {
          "term": "hbv testing",
          "heading": false
        },
        {
          "term": "hcv infection",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "prep users",
          "heading": false
        },
        {
          "term": "prep services",
          "heading": false
        },
        {
          "term": "endemic countries",
          "heading": false
        },
        {
          "term": "hbsag",
          "heading": false
        }
      ],
      "extract": "Testing PrEP users for HBsAg once, at or within one to three months of PrEP initiation (or later if not available around initiation), is strongly encouraged, particularly in highly endemic countries. TDF-based daily or event- driven oral PrEP and the DVR can be safely offered to persons with HBV infection. There are specific considerations regarding offering CAB-LA to people with HBV (Box 3). HBV testing is not a",
      "extractCut": true
    },
    {
      "id": "sec-013-hepatitis-c-virus",
      "number": null,
      "title": "Hepatitis C virus",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 17,
      "labelStart": "7",
      "labelEnd": "8",
      "words": 579,
      "summary": {
        "text": "Recommends hepatitis C antibody testing at PrEP start and yearly for populations at high risk, while making clear that testing is not a requirement for PrEP. It covers referral for treatment, HCV self-testing and specific considerations for long-acting cabotegravir in people with hepatitis C.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hcv serology",
          "heading": false
        },
        {
          "term": "hcv self-testing",
          "heading": false
        },
        {
          "term": "hcv treatment",
          "heading": false
        },
        {
          "term": "hcv testing",
          "heading": false
        },
        {
          "term": "hcv infection",
          "heading": false
        },
        {
          "term": "hcv care",
          "heading": false
        },
        {
          "term": "hbv treatment",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        }
      ],
      "extract": "HCV antibody testing is strongly encouraged at or within one to three months of PrEP initiation (or later if not available around initiation), and every 12 months thereafter, where PrEP services are provided to populations at high risk of HCV infection. Risks of HCV vary across settings, and populations at high risk of HCV include, but are not limited to, cisgender men and transgender women who have sex with men,",
      "extractCut": true
    },
    {
      "id": "sec-014-rationale",
      "number": null,
      "title": "Rationale",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 18,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 464,
      "summary": {
        "text": "Explains the rationale for the hepatitis guidance, citing global estimates of hepatitis B and C burden and the 2030 elimination goal. It revises earlier advice by stating that hepatitis B infection does not rule out event-driven PrEP, because clinical relapse is rare, and discusses PrEP choices for pregnant people living with hepatitis B.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hbv relapse",
          "heading": false
        },
        {
          "term": "chronic hbv",
          "heading": false
        },
        {
          "term": "hbv infection",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "hcv infection",
          "heading": false
        },
        {
          "term": "clinical relapse",
          "heading": false
        },
        {
          "term": "prep services",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        }
      ],
      "extract": "WHO estimates that in 2019, there were 296 million people living with chronic HBV infection and 58 million people living with HCV infection worldwide (31). An estimated 1.1 million deaths in 2019 were due to HBV and HCV infection. The Global Health Sector Strategy on Viral Hepatitis, approved by the World Health Assembly in 2016, set the goal to eliminate viral hepatitis as a major public health threat by 2030 (32).",
      "extractCut": true
    },
    {
      "id": "sec-015-prep-and-kidney-function",
      "number": null,
      "title": "PrEP and kidney function",
      "level": 1,
      "pageStart": 18,
      "pageEnd": 20,
      "labelStart": "9",
      "labelEnd": "11",
      "words": 971,
      "summary": {
        "text": "Sets out guidance on kidney function and TDF-based oral PrEP: impaired kidney function is a contraindication, but testing is optional for people under 30 without comorbidities and can be limited for others. It advises that waiting for results should not delay PrEP and that tests be repeated before stopping. Notes cover estimating kidney function, including during pregnancy and gender-affirming hormone use.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "kidney function",
          "heading": true
        },
        {
          "term": "egfr",
          "heading": false
        },
        {
          "term": "serum creatinine",
          "heading": false
        },
        {
          "term": "gender-affirming hormones",
          "heading": false
        },
        {
          "term": "assigned male",
          "heading": false
        }
      ],
      "extract": "Impaired kidney function, indicated by an eGFR of <60 mL/min per 1.73 m2 or an estimated creatinine clearance of <60 mL/min, is a contraindication for the use of TDF-based oral PrEP. Measuring kidney function in potential PrEP users at initiation and during PrEP continuation is suggested for some populations. Table 2 outlines suggested procedures (applicable to oral daily PrEP or ED-PrEP). Box 4 provides suggestions",
      "extractCut": true
    },
    {
      "id": "sec-016-rationale",
      "number": null,
      "title": "Rationale",
      "level": 2,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 244,
      "summary": {
        "text": "Explains the rationale for reduced kidney testing, citing meta-analyses showing mostly mild, reversible kidney effects and data from over 18 000 people screened in which abnormal values were rare and increased with age.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "creatinine clearance",
          "heading": false
        },
        {
          "term": "min creatinine",
          "heading": false
        },
        {
          "term": "baseline creatinine",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "kidney-related adverse",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "subsequent measurement",
          "heading": false
        }
      ],
      "extract": "Multiple systematic reviews and meta-analyses of randomized controlled trials (RCTs) found that individuals taking TDF-based oral PrEP have, on average, a higher risk of experiencing kidney-related adverse events compared with individuals taking placebos (46–48), but these adverse events tend to be mild, nonprogressive, and reversible after PrEP discontinuation. Severe kidney-related adverse events are very rare. An",
      "extractCut": true
    },
    {
      "id": "sec-017-hiv-self-testing-hivst-for-prep",
      "number": null,
      "title": "HIV self-testing (HIVST) for PrEP",
      "level": 1,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 3,
      "summary": {
        "text": "A heading fragment for the section on HIV self-testing for PrEP.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "(HIVST) for PrEP",
      "extractCut": false
    },
    {
      "id": "sec-018-hivst-and-prep",
      "number": null,
      "title": "HIVST and PrEP",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 409,
      "summary": {
        "text": "Describes how HIV self-testing can support PrEP, drawing on COVID-19 experience and a review showing fewer clinic visits and testing between visits. It outlines three uses—demand generation and linkage, PrEP initiation, and continuation—and notes the need for community engagement and further operational research.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hivst",
          "heading": true
        },
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "hivst-supported prep",
          "heading": false
        },
        {
          "term": "prep delivery",
          "heading": false
        },
        {
          "term": "increase prep",
          "heading": false
        },
        {
          "term": "prep continuation",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "prep users",
          "heading": false
        }
      ],
      "extract": "HIVST could be an important tool to enable countries to increase access to PrEP and uptake, persistence and effective use. Since the beginning of the COVID-19 pandemic, WHO has supported HIVST to maintain PrEP services (51), and several countries have integrated HIVST into their PrEP programming to initiate and continue clients on PrEP (see Box 6 and 10 in next section). A literature review found evidence that HIVST",
      "extractCut": true
    },
    {
      "id": "sec-019-what-is-hivst",
      "number": null,
      "title": "What is HIVST?",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 23,
      "labelStart": "12",
      "labelEnd": "14",
      "words": 1425,
      "summary": {
        "text": "Explains what HIV self-testing is, its WHO recommendation since 2016 and the prequalified products available. It discusses using self-testing to start PrEP outside clinics despite limited evidence, addressing concerns about acute infection and drug resistance. Modelling summarised here suggests that self-testing may miss some infections but that drug-resistance prevalence stays similar across scenarios.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hivst",
          "heading": true
        },
        {
          "term": "reactive hivst",
          "heading": false
        },
        {
          "term": "prequalified hivst",
          "heading": false
        },
        {
          "term": "hivst-supported prep",
          "heading": false
        },
        {
          "term": "hivst supported",
          "heading": false
        },
        {
          "term": "prep continuation",
          "heading": false
        },
        {
          "term": "prep users",
          "heading": false
        },
        {
          "term": "prep initiation",
          "heading": false
        }
      ],
      "extract": "In HIVST, people collect their own specimen (generally oral fluid or fingerprick whole blood) using a simple rapid HIV test and then perform the test and interpret their result, often in private or with someone they trust. WHO has recommended HIVST as an approach to HIV testing services since 2016 (4), and the approach has been scaled up globally with nearly 100 countries reporting national policies.6 Currently,",
      "extractCut": true
    },
    {
      "id": "sec-020-rationale",
      "number": null,
      "title": "Rationale",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 24,
      "labelStart": "14",
      "labelEnd": "15",
      "words": 88,
      "summary": {
        "text": "Summarises a systematic review of self-testing for PrEP, including a Kenyan trial in which six-month dispensing with self-testing halved clinic visits without reducing persistence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep dispensing",
          "heading": false
        },
        {
          "term": "prep initiation",
          "heading": false
        },
        {
          "term": "clinic visits",
          "heading": false
        },
        {
          "term": "studies evaluated",
          "heading": false
        }
      ],
      "extract": "A systematic review on HIVST for PrEP initiation and continuation (52) identified three completed RCTs that evaluated PrEP continuation after initiation in health care facilities, while no studies evaluated HIVST-based PrEP initiation. All studies evaluated oral PrEP. An RCT in Kenya that evaluated six-month PrEP dispensing supported with HIVST between clinic visits found that PrEP clinic visits were halved, while",
      "extractCut": true
    },
    {
      "id": "sec-021-building-blocks-of-differentiated-prep-service-d",
      "number": null,
      "title": "Building blocks of differentiated PrEP service delivery",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 49,
      "summary": {
        "text": "Introduces differentiated PrEP delivery, noting the shift away from clinic-only physician prescribing that accelerated during COVID-19.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "differentiated",
          "heading": true
        },
        {
          "term": "delivery",
          "heading": true
        }
      ],
      "extract": "delivery In many countries, individuals interested in PrEP must go to a health care facility (often an HIV clinic) to obtain a prescription from a medical provider (often a physician). In recent years, and particularly during the COVID-19 pandemic (60), the shift towards differentiated PrEP service delivery has accelerated.",
      "extractCut": false
    },
    {
      "id": "sec-022-differentiated-prep-service-delivery-when-where",
      "number": null,
      "title": "Differentiated PrEP service delivery: When, where, who and what to deliver",
      "level": 1,
      "pageStart": 24,
      "pageEnd": 25,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 546,
      "summary": {
        "text": "Defines differentiated PrEP service delivery as person- and community-centred and links it to the global health sector strategies. It presents the four building blocks (when, where, who and what), which can differ between initiation, continuation and re-initiation and across PrEP products.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "differentiated prep",
          "heading": true
        },
        {
          "term": "prep service",
          "heading": true
        },
        {
          "term": "service delivery",
          "heading": true
        },
        {
          "term": "prep refill",
          "heading": false
        },
        {
          "term": "prep initiation",
          "heading": false
        },
        {
          "term": "prep products",
          "heading": false
        },
        {
          "term": "prep assessment",
          "heading": false
        },
        {
          "term": "building blocks",
          "heading": false
        }
      ],
      "extract": "delivery: When, where, who and what to deliver A differentiated PrEP service delivery approach is person- and community-centred and adapts services to the needs and preferences of the people who are interested in and could benefit from PrEP. Differentiated PrEP service delivery may also support more efficient and cost–effective use of health care resources. WHO recommends differentiated service delivery for HIV",
      "extractCut": true
    },
    {
      "id": "sec-023-where-to-deliver-prep",
      "number": null,
      "title": "Where to deliver PrEP",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 27,
      "labelStart": "16",
      "labelEnd": "18",
      "words": 792,
      "summary": {
        "text": "Sets out barriers to PrEP in health facilities, such as stigma, lack of privacy, distance, costs and long waits, as well as provider-side barriers. It argues that oral PrEP and the ring have few required components and can be delivered in community settings, while more research is needed for long-acting cabotegravir. Evidence and provider views on community-based delivery follow.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "prep delivery",
          "heading": false
        },
        {
          "term": "prep providers",
          "heading": false
        },
        {
          "term": "prep service",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "community-based delivery",
          "heading": false
        },
        {
          "term": "telehealth models",
          "heading": false
        },
        {
          "term": "delivery sites",
          "heading": false
        }
      ],
      "extract": "There are a range of barriers to PrEP access, uptake, persistence and effective use associated with service delivery in health care facilities. These include actual or perceived lack of privacy, stigma and discrimination, negative attitudes of health care providers, travel distance, direct and opportunity costs for clients, frequency of required clinic visits for continuation, lengthy waiting times and inconvenient",
      "extractCut": true
    },
    {
      "id": "sec-024-prep-in-fixed-and-mobile-community-settings",
      "number": null,
      "title": "PrEP in fixed and mobile community settings",
      "level": 2,
      "pageStart": 27,
      "pageEnd": 29,
      "labelStart": "18",
      "labelEnd": "20",
      "words": 885,
      "summary": {
        "text": "Describes oral PrEP delivery in fixed and mobile community sites, such as NGO centres and vans, and the importance of partnerships with community organizations and integrated services. A box summarises review evidence, including the SEARCH trial in Kenya and Uganda and the Love O2O study in Thailand, and an example from Viet Nam is pictured.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mobile prep",
          "heading": true
        },
        {
          "term": "fixed community",
          "heading": true
        },
        {
          "term": "prep initiations",
          "heading": false
        },
        {
          "term": "prep persistence",
          "heading": false
        },
        {
          "term": "prep delivery",
          "heading": false
        },
        {
          "term": "prep clients",
          "heading": false
        },
        {
          "term": "community settings",
          "heading": true
        },
        {
          "term": "oral prep",
          "heading": false
        }
      ],
      "extract": "Service models that deliver oral PrEP in fixed community sites (such as through nongovernmental organizations) and mobile and semimobile sites (for example, vans parked in community settings) have been implemented. A systematic review (Box 7) (63) identified diverse models demonstrating the feasibility of these approaches in a range of countries, but data on effectiveness were limited. In addition to considerations",
      "extractCut": true
    },
    {
      "id": "sec-025-telehealth-for-prep",
      "number": null,
      "title": "Telehealth for PrEP",
      "level": 2,
      "pageStart": 29,
      "pageEnd": 31,
      "labelStart": "20",
      "labelEnd": "22",
      "words": 913,
      "summary": {
        "text": "Describes telehealth platforms for delivering PrEP, which WHO supports as an additional option provided data security and confidentiality are protected. It lists aspects of service delivery that telehealth can support, such as risk assessment, home delivery of self-test kits and prescriptions. Evidence from case studies and ongoing US trials is summarised, with a photo from a Brazilian project.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "telehealth",
          "heading": true
        },
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "prep persistence",
          "heading": false
        },
        {
          "term": "telehealth platforms",
          "heading": false
        },
        {
          "term": "prep initiations",
          "heading": false
        },
        {
          "term": "telehealth models",
          "heading": false
        },
        {
          "term": "telehealth services",
          "heading": false
        },
        {
          "term": "telehealth counselling",
          "heading": false
        }
      ],
      "extract": "The use of information and telecommunication technologies to create virtual platforms for delivering PrEP services has the potential to remove barriers to PrEP uptake and persistence and support effective use of PrEP. WHO recommends that online delivery of HIV, viral hepatitis and STI services to key populations may be offered as an additional option, while ensuring that data security and confidentiality are",
      "extractCut": true
    },
    {
      "id": "sec-026-prep-delivery-in-pharmacies",
      "number": null,
      "title": "PrEP delivery in pharmacies",
      "level": 2,
      "pageStart": 31,
      "pageEnd": 32,
      "labelStart": "22",
      "labelEnd": "23",
      "words": 563,
      "summary": {
        "text": "Explains that pharmacies can be more accessible and convenient than clinics and may expand PrEP access, though effectiveness and cost-effectiveness of pharmacy delivery remain unknown. It sets out what pharmacists need, such as legal authority, testing infrastructure and training, and cites Kenyan experience showing similar uptake and persistence, noting that legal changes are needed for pharmacists to prescribe PrEP.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep delivery",
          "heading": true
        },
        {
          "term": "pharmacies",
          "heading": true
        },
        {
          "term": "prep clients",
          "heading": false
        },
        {
          "term": "pharmacy prep",
          "heading": false
        },
        {
          "term": "retail pharmacies",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "prep services",
          "heading": false
        },
        {
          "term": "prep users",
          "heading": false
        }
      ],
      "extract": "Pharmacies can be more accessible, acceptable and convenient for clients than health care facilities. In resource-limited settings, individuals commonly first seek health care services from pharmacies before going to clinics (72,73). The WHO Guideline on Self- Care Interventions for Health and Well-Being (74) notes that providing PrEP through pharmacies may present an opportunity to expand access to PrEP. However,",
      "extractCut": true
    },
    {
      "id": "sec-027-who-to-deliver-prep",
      "number": null,
      "title": "Who to deliver PrEP",
      "level": 2,
      "pageStart": 32,
      "pageEnd": 33,
      "labelStart": "23",
      "labelEnd": "24",
      "words": 618,
      "summary": {
        "text": "Contrasts WHO task-sharing recommendations for ART with PrEP, which in most countries is prescribed by clinicians while lay providers handle other tasks such as risk assessment and HIV testing. It argues that sharing PrEP tasks with peers and community health workers may improve efficiency and acceptability, noting research needs for long-acting cabotegravir and requirements for training, quality assurance, clinical oversight and fair pay.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "prep services",
          "heading": false
        },
        {
          "term": "trained nurses",
          "heading": false
        },
        {
          "term": "task sharing",
          "heading": false
        },
        {
          "term": "lay providers",
          "heading": false
        },
        {
          "term": "community-led services",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        },
        {
          "term": "deliver",
          "heading": true
        }
      ],
      "extract": "For HIV treatment, WHO recommends (4) that 1) trained nonphysician clinicians, nurses and midwives can initiate and maintain ART, and 2) trained and supervised community health workers can dispense ART and lay providers can distribute ART. For PrEP, in most countries a clinician prescribes PrEP, while other health care providers (for example, lay providers) may deliver other aspects of PrEP services, such as",
      "extractCut": true
    },
    {
      "id": "sec-028-when-and-what-services-to-deliver",
      "number": null,
      "title": "When and what services to deliver",
      "level": 2,
      "pageStart": 33,
      "pageEnd": 35,
      "labelStart": "24",
      "labelEnd": "26",
      "words": 1625,
      "summary": {
        "text": "Discusses when and what PrEP services to deliver, starting with multi-month dispensing, which is standard for ART and is being adapted for PrEP after an initial one-month visit, with examples from Viet Nam, Zimbabwe and a Kenyan trial of six-month dispensing with HIV self-testing. It then covers integrating PrEP with other services, such as gender-affirming care, harm reduction, antenatal and family planning services, and a status-neutral approach to testing. It ends with a case study from Glasgow on PrEP for people who inject drugs, where staffing intensity limits expansion.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "differentiated prep",
          "heading": false
        },
        {
          "term": "prep users",
          "heading": false
        },
        {
          "term": "prep supplies",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "prep services",
          "heading": false
        },
        {
          "term": "integrating prep",
          "heading": false
        },
        {
          "term": "prep delivery",
          "heading": false
        },
        {
          "term": "among prep",
          "heading": false
        }
      ],
      "extract": "Multi-month dispensing (MMD) WHO recommends that people living with HIV established on ART should be offered three-to-six– month ART refills, preferably lasting six months (4). MMD of ART has been found to be feasible and cost- saving for providers and clients in a range of countries, and COVID-19 has accelerated adoption of ART MMD (83). For oral PrEP, a one-month supply is commonly provided at initiation,",
      "extractCut": true
    },
    {
      "id": "sec-029-research-gaps",
      "number": null,
      "title": "Research gaps",
      "level": 2,
      "pageStart": 35,
      "pageEnd": 36,
      "labelStart": "26",
      "labelEnd": "27",
      "words": 244,
      "summary": {
        "text": "Identifies research gaps for differentiated PrEP delivery, calling for implementation science and quasi-experimental methods to measure effects on uptake, persistence and effective use. It notes that evidence is concentrated among men who have sex with men and young women in a few countries, and that experience with the dapivirine ring and long-acting cabotegravir is still lacking.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "differentiated prep",
          "heading": false
        },
        {
          "term": "prep service",
          "heading": false
        },
        {
          "term": "community-based services",
          "heading": false
        },
        {
          "term": "service delivery",
          "heading": false
        },
        {
          "term": "delivery models",
          "heading": false
        },
        {
          "term": "additional evidence",
          "heading": false
        },
        {
          "term": "implementation science",
          "heading": false
        },
        {
          "term": "diverse",
          "heading": false
        }
      ],
      "extract": "While the feasibility of a range of differentiated PrEP service delivery models has been demonstrated, additional evidence of effectiveness of PrEP-related outcomes (uptake, persistence and effective use) is needed. Implementation science and quasi- experimental approaches, such as difference-in- differences methods for pre–post evaluations of interventions, could provide robust evidence on effectiveness,",
      "extractCut": true
    },
    {
      "id": "sec-030-references",
      "number": null,
      "title": "References",
      "level": 1,
      "pageStart": 36,
      "pageEnd": 42,
      "labelStart": "27",
      "labelEnd": "33",
      "words": 3779,
      "summary": {
        "text": "The reference list for the technical brief on differentiated and simplified PrEP delivery, citing global HIV strategies, WHO HIV guidelines and studies of PrEP delivery models.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bitstreams retrieve",
          "heading": false
        },
        {
          "term": "rest bitstreams",
          "heading": false
        },
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "pre-exposure prophylaxis",
          "heading": false
        },
        {
          "term": "preexposure prophylaxis",
          "heading": false
        },
        {
          "term": "hiv pre-exposure",
          "heading": false
        },
        {
          "term": "tenofovir disoproxil",
          "heading": false
        },
        {
          "term": "oral pre-exposure",
          "heading": false
        }
      ],
      "extract": "1. Schaefer R, Schmidt HMA, Ravasi G, Mozalevskis A, Rewari BB, Lule F, et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021;8(8):e502-e510. doi:10.1016/S2352- 3018(21)00127-2 2. Political declaration on HIV and AIDS: ending inequalities and getting on track to end aids by 2030. New York City, NY: United Nations General Assembly; 2021",
      "extractCut": true
    },
    {
      "id": "sec-031-annex-1-summary-of-mathematical-modelling-of-hiv",
      "number": null,
      "title": "Annex 1: Summary of mathematical modelling of HIVST for PrEP in Kenya",
      "level": 1,
      "pageStart": 42,
      "pageEnd": 43,
      "labelStart": "33",
      "labelEnd": "34",
      "words": 498,
      "summary": {
        "text": "Annex 1, summarizing mathematical modelling of HIV self-testing for community-based oral PrEP delivery in Kenya. It concludes that expanding PrEP could avert nearly half of new infections over 20 years and that self-testing-based delivery could be effective, with only small increases in inappropriate PrEP use and drug resistance compared with provider testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hivst",
          "heading": true
        },
        {
          "term": "hivst scenario",
          "heading": false
        },
        {
          "term": "blood-based hivst",
          "heading": false
        },
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "oral hivst",
          "heading": false
        },
        {
          "term": "prep initiations",
          "heading": false
        },
        {
          "term": "prep coverage",
          "heading": false
        },
        {
          "term": "prep provision",
          "heading": false
        }
      ],
      "extract": "mathematical modelling of HIVST for PrEP in Kenya Background Community-based oral PrEP provision has the potential to expand PrEP access. HIVST can facilitate community- based PrEP delivery by enabling non-health-care providers to conduct HIV testing for PrEP initiation and continuation. However, HIVST can have lower test sensitivity than facility-based RDTs, potentially leading to inappropriate PrEP provision to",
      "extractCut": true
    },
    {
      "id": "sec-032-annex-2-background-and-methods-on-the-global-pre",
      "number": null,
      "title": "Annex 2: Background and methods on the global PrEP provider study",
      "level": 1,
      "pageStart": 43,
      "pageEnd": 45,
      "labelStart": "34",
      "labelEnd": "36",
      "words": 619,
      "summary": {
        "text": "Annex 2, describing the methods of a WHO-supported global survey and in-depth interviews of PrEP providers carried out between November 2021 and February 2022 on service practices and views of new PrEP products. It explains how questions were developed and translated and lists participating providers by WHO region and country.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep provider",
          "heading": true
        },
        {
          "term": "global prep",
          "heading": true
        },
        {
          "term": "survey respondents",
          "heading": false
        },
        {
          "term": "provider study",
          "heading": true
        },
        {
          "term": "online survey",
          "heading": false
        },
        {
          "term": "in-depth interviews",
          "heading": false
        },
        {
          "term": "prep products",
          "heading": false
        },
        {
          "term": "eastern mediterranean",
          "heading": false
        }
      ],
      "extract": "methods on the global PrEP provider study WHO supported a global study of PrEP providers, comprising an online survey and in-depth interviews, from November 2021 through February 2022. The survey aimed to understand current service delivery practices as well as perspectives on new PrEP products. Follow-up interviews with survey participants were conducted to gain additional insights and to offer an opportunity for",
      "extractCut": true
    },
    {
      "id": "sec-033-annex-3-summary-of-a-review-of-prep-services-for",
      "number": null,
      "title": "Annex 3: Summary of a review of PrEP services for people who inject drugs",
      "level": 1,
      "pageStart": 45,
      "pageEnd": 46,
      "labelStart": "36",
      "labelEnd": "37",
      "words": 494,
      "summary": {
        "text": "Annex 3, summarizing a review of PrEP services for people who inject drugs, which found limited availability and use. It recommends expanding PrEP within harm reduction programmes, preferably community-based and peer-led, and lists service models found, before ending with WHO's contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "inject drugs",
          "heading": true
        },
        {
          "term": "prep services",
          "heading": true
        },
        {
          "term": "people",
          "heading": true
        },
        {
          "term": "harm reduction",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "drug treatment",
          "heading": false
        },
        {
          "term": "service delivery",
          "heading": false
        },
        {
          "term": "peer-led",
          "heading": false
        }
      ],
      "extract": "review of PrEP services for people who inject drugs Background Since 2015, WHO has recommended offering TDF-based oral PrEP to all people at substantial risk of HIV as part of combination HIV prevention, but little is known about the extent to which this recommendation has been implemented for people who inject drugs. The objectives of this study were to review literature on perspectives on and use of PrEP by people",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "oral prep",
      "heading": true
    },
    {
      "term": "differentiated prep",
      "heading": true
    },
    {
      "term": "prep delivery",
      "heading": true
    },
    {
      "term": "prep services",
      "heading": true
    },
    {
      "term": "prep initiation",
      "heading": true
    },
    {
      "term": "prep persistence",
      "heading": false
    },
    {
      "term": "testing prep",
      "heading": false
    },
    {
      "term": "prep continuation",
      "heading": true
    },
    {
      "term": "prep clients",
      "heading": false
    },
    {
      "term": "prep uptake",
      "heading": false
    },
    {
      "term": "prep provider",
      "heading": true
    },
    {
      "term": "prep implementation",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "C1",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "iii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 5,
      "label": "iv",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 6,
      "label": "v",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "vi",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 8,
      "label": "vii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 9,
      "label": "viii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 11,
      "label": "2",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 12,
      "label": "3",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 13,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 14,
      "label": "5",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 15,
      "label": "6",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 16,
      "label": "7",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 17,
      "label": "8",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 18,
      "label": "9",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 19,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 20,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 21,
      "label": "12",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 23,
      "label": "14",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 24,
      "label": "15",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 25,
      "label": "16",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 26,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "18",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 28,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "20",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 30,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "22",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 32,
      "label": "23",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 33,
      "label": "24",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 34,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "26",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 36,
      "label": "27",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 37,
      "label": "28",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "30",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "31",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 41,
      "label": "32",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "34",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 44,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 45,
      "label": "36",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 46,
      "label": "37",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "box",
      "number": "1",
      "title": "WHO recommendations on PrEP",
      "page": 10,
      "pageLabel": "1",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "2",
      "title": "A note on substantial risk of HIV",
      "page": 11,
      "pageLabel": "2",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "1",
      "title": "How to start and stop oral PrEP for those eligible for ED-PrEP and those not eligible",
      "page": 13,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "1",
      "title": "Starting, using and stopping TDF-based oral PrEP safely",
      "page": 13,
      "pageLabel": "4",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3",
      "title": "CAB-LA for people with HBV and",
      "page": 16,
      "pageLabel": "7",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "Suggested procedures for measuring kidney function for TDF-containing oral PrEP",
      "page": 19,
      "pageLabel": "10",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "4",
      "title": "Measuring kidney function",
      "page": 20,
      "pageLabel": "11",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "5",
      "title": "Key research questions for HIVST",
      "page": 23,
      "pageLabel": "14",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "The building blocks of differentiated PrEP service delivery",
      "page": 25,
      "pageLabel": "16",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "6",
      "title": "Provider perspectives on",
      "page": 26,
      "pageLabel": "17",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "7",
      "title": "Evidence on PrEP delivery in fixed and mobile community settings",
      "page": 27,
      "pageLabel": "18",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "2",
      "title": "PrEP on Wheels in Dong Nai province, Viet Nam (January 2021)",
      "page": 28,
      "pageLabel": "19",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "8",
      "title": "Bringing PrEP closer to home in Viet Nam",
      "page": 28,
      "pageLabel": "19",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "9",
      "title": "Evidence on telehealth for PrEP",
      "page": 29,
      "pageLabel": "20",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "3",
      "title": "A PrEP1519 participant receives an HIV prevention kit with an HIVST at home,",
      "page": 30,
      "pageLabel": "21",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "10",
      "title": "Telehealth for PrEP during COVID-19 in Brazil",
      "page": 30,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "4",
      "title": "PrEP delivery in a pharmacy,",
      "page": 31,
      "pageLabel": "22",
      "confidence": 0.7,
      "evidence": [
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "11",
      "title": "Evidence about PrEP delivery in",
      "page": 31,
      "pageLabel": "22",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "12",
      "title": "Oral PrEP initiation and continuation in private pharmacies in Kenya",
      "page": 31,
      "pageLabel": "22",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "13",
      "title": "PrEP for people who inject drugs in Glasgow",
      "page": 34,
      "pageLabel": "25",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "A2.1",
      "title": "Regional and country income level distribution of online survey participantsa,b",
      "page": 43,
      "pageLabel": "34",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "A2.2",
      "title": "Geographic representation of participants in in-depth interviews on PrEP",
      "page": 44,
      "pageLabel": "35",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p001-1",
      "file": "images/img-p001-1.webp",
      "page": 1,
      "narratives": {
        "en": "Cover photograph of a smiling woman with long reddish braided hair, wearing a red top.",
        "ar": "صورة غلاف لامرأة مبتسمة ذات ضفائر طويلة ضاربة إلى الحمرة، ترتدي قميصاً أحمر.",
        "zh": "封面照片：一位微笑的女性，留着偏红色的长发辫，身穿红色上衣。",
        "es": "Fotografía de portada de una mujer sonriente con largas trenzas rojizas y una blusa roja.",
        "fr": "Photographie de couverture d’une femme souriante aux longues tresses rousses, vêtue d’un haut rouge.",
        "ru": "Фотография на обложке: улыбающаяся женщина с длинными рыжеватыми косичками в красной кофте."
      },
      "state": "draft"
    },
    {
      "id": "img-p001-2",
      "file": "images/img-p001-2.webp",
      "page": 1,
      "narratives": {
        "en": "Cover photograph of a young woman in a green top and patterned wrap skirt standing outdoors under a cloudy sky at dusk, with trees behind her.",
        "ar": "صورة غلاف لامرأة شابة ترتدي قميصاً أخضر وتنورة ملفوفة مزخرفة، تقف في الهواء الطلق تحت سماء غائمة عند الغسق وخلفها أشجار.",
        "zh": "封面照片：一位身穿绿色上衣和花纹裹裙的年轻女性在黄昏多云的天空下站在户外，身后有树木。",
        "es": "Fotografía de portada de una mujer joven con blusa verde y falda cruzada estampada, de pie al aire libre bajo un cielo nublado al atardecer, con árboles detrás.",
        "fr": "Photographie de couverture d’une jeune femme en haut vert et jupe portefeuille à motifs, debout en extérieur sous un ciel nuageux au crépuscule, avec des arbres derrière elle.",
        "ru": "Фотография на обложке: молодая женщина в зеленой кофте и пестрой юбке-запахе стоит на улице под облачным вечерним небом на фоне деревьев."
      },
      "state": "draft"
    },
    {
      "id": "img-p001-3",
      "file": "images/img-p001-3.webp",
      "page": 1,
      "narratives": {
        "en": "Black-and-white cover photograph of a person applying eyebrow make-up while looking into a hand mirror.",
        "ar": "صورة غلاف بالأبيض والأسود لشخص يضع مستحضرات تجميل على حاجبيه وهو ينظر في مرآة يدوية.",
        "zh": "黑白封面照片：一个人对着手镜描画眉毛。",
        "es": "Fotografía de portada en blanco y negro de una persona que se maquilla las cejas mirándose en un espejo de mano.",
        "fr": "Photographie de couverture en noir et blanc d’une personne qui se maquille les sourcils en se regardant dans un miroir à main.",
        "ru": "Черно-белая фотография на обложке: человек подкрашивает брови, глядя в ручное зеркало."
      },
      "state": "draft"
    },
    {
      "id": "img-p001-4",
      "file": "images/img-p001-4.webp",
      "page": 1,
      "narratives": {
        "en": "Cover photograph of a smiling young man in a dark blue T-shirt against a dark background.",
        "ar": "صورة غلاف لشاب مبتسم يرتدي قميصاً أزرق داكناً على خلفية داكنة.",
        "zh": "封面照片：一位身穿深蓝色T恤的年轻男子在深色背景前微笑。",
        "es": "Fotografía de portada de un hombre joven sonriente con camiseta azul oscuro sobre fondo oscuro.",
        "fr": "Photographie de couverture d’un jeune homme souriant en t-shirt bleu foncé sur fond sombre.",
        "ru": "Фотография на обложке: улыбающийся молодой человек в темно-синей футболке на темном фоне."
      },
      "state": "draft"
    },
    {
      "id": "img-p001-5",
      "file": "images/img-p001-5.webp",
      "page": 1,
      "narratives": {
        "en": "Cover photograph of a smiling young woman wearing a teal jacket over a black T-shirt with green lettering.",
        "ar": "صورة غلاف لامرأة شابة مبتسمة ترتدي سترة فيروزية فوق قميص أسود عليه حروف خضراء.",
        "zh": "封面照片：一位微笑的年轻女性，身穿青绿色外套，内搭印有绿色字母的黑色T恤。",
        "es": "Fotografía de portada de una mujer joven sonriente con chaqueta verde azulado sobre una camiseta negra con letras verdes.",
        "fr": "Photographie de couverture d’une jeune femme souriante portant une veste bleu-vert sur un t-shirt noir à lettres vertes.",
        "ru": "Фотография на обложке: улыбающаяся молодая женщина в бирюзовой куртке поверх черной футболки с зелеными буквами."
      },
      "state": "draft"
    },
    {
      "id": "img-p001-6",
      "file": "images/img-p001-6.webp",
      "page": 1,
      "narratives": {
        "en": "Cover photograph of a smiling man with a beard and a cap, sitting on a bed with a striped cover in front of a dark painted wall.",
        "ar": "صورة غلاف لرجل ملتحٍ مبتسم يرتدي قبعة، يجلس على سرير بغطاء مخطط أمام جدار داكن مطلي.",
        "zh": "封面照片：一位留胡子、戴帽子的男子面带微笑，坐在铺有条纹床罩的床上，背后是一面深色彩绘墙。",
        "es": "Fotografía de portada de un hombre sonriente con barba y gorra, sentado en una cama con colcha de rayas delante de una pared oscura pintada.",
        "fr": "Photographie de couverture d’un homme barbu et souriant portant une casquette, assis sur un lit à couverture rayée devant un mur sombre peint.",
        "ru": "Фотография на обложке: улыбающийся бородатый мужчина в кепке сидит на кровати с полосатым покрывалом у темной расписанной стены."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p013",
      "file": "figures/vfig-p013.webp",
      "page": 13,
      "shows": [
        "Table 1",
        "Figure 1"
      ],
      "narratives": {
        "en": "Page render with the end of Table 1 and Figure 1. The table gives oral PrEP dosing by population: cisgender men and trans and gender diverse people assigned male at birth with sexual exposure who are not taking exogenous estradiol-based hormones take a double dose 2–24 hours before exposure, one dose per day, and one dose per day until two days after the last exposure; other populations (including cisgender women, people taking estradiol-based hormones and people preventing HIV acquisition from injecting practices) take one dose daily for seven days before exposure, one dose per day, and one dose daily for seven days after the last exposure. Figure 1 shows day-by-day timelines with pill icons: for those eligible for ED-PrEP, a double dose then daily doses through two days after sex (within or beyond 24 hours of the initial dose); for those not eligible, seven daily doses before exposure, continued daily dosing, and seven daily doses after the last exposure.",
        "ar": "عرض لصفحة يتضمن نهاية الجدول 1 والشكل 1. يعرض الجدول جرعات الوقاية الفموية قبل التعرض (PrEP) حسب الفئة السكانية: الرجال المتوافقو الجنس والأشخاص العابرون جنسياً والمتنوعون جنسانياً المحددون ذكوراً عند الولادة الذين يتعرضون جنسياً ولا يتناولون هرمونات خارجية قائمة على الإستراديول يتناولون جرعة مضاعفة قبل التعرض بـ 2–24 ساعة، ثم جرعة واحدة يومياً، ثم جرعة يومياً حتى يومين بعد آخر تعرض؛ أما الفئات الأخرى (بما فيها النساء المتوافقات الجنس ومن يتناولون هرمونات قائمة على الإستراديول ومن يقون أنفسهم من اكتساب الفيروس عبر ممارسات الحقن) فتتناول جرعة يومياً لمدة سبعة أيام قبل التعرض، ثم جرعة يومياً، ثم جرعة يومياً لمدة سبعة أيام بعد آخر تعرض. ويعرض الشكل 1 جداول زمنية يوماً بيوم مع أيقونات أقراص: للمؤهلين للوقاية المرتبطة بالحدث (ED-PrEP)، جرعة مضاعفة ثم جرعات يومية حتى يومين بعد الجماع (خلال 24 ساعة من الجرعة الأولى أو بعدها)؛ ولغير المؤهلين، سبع جرعات يومية قبل التعرض، ثم الاستمرار يومياً، ثم سبع جرعات يومية بعد آخر تعرض.",
        "zh": "页面渲染图，包含表1结尾和图1。表格按人群列出口服暴露前预防（PrEP）的用药方法：有性暴露且未使用外源性雌二醇类激素的顺性别男性及出生时被指定为男性的跨性别和性别多元者，在潜在暴露前2–24小时服用双倍剂量，此后每天一剂，并每天一剂直至最后一次暴露后两天；其他人群（包括顺性别女性、使用雌二醇类激素者以及为预防注射行为感染艾滋病毒而使用PrEP者）在潜在暴露前连续七天每天一剂，此后每天一剂，并在最后一次暴露后连续七天每天一剂。图1以药片图标逐日展示时间线：符合事件驱动PrEP（ED-PrEP）条件者先服双倍剂量，然后每天服药直至性行为后两天（性行为在首次剂量后24小时内或超过24小时）；不符合条件者在暴露前每天服药七天，持续每天服药，并在最后一次暴露后每天服药七天。",
        "es": "Imagen de página con el final del cuadro 1 y la figura 1. El cuadro indica la posología de la PrEP oral por población: los hombres cisgénero y las personas trans y de género diverso a las que se asignó el sexo masculino al nacer, con exposición sexual y que no toman hormonas exógenas a base de estradiol, toman una dosis doble entre 2 y 24 horas antes de la exposición, una dosis al día y una dosis al día hasta dos días después de la última exposición; las demás poblaciones (incluidas las mujeres cisgénero, las personas que toman hormonas a base de estradiol y las personas que usan la PrEP para prevenir la infección por el VIH asociada a prácticas de inyección) toman una dosis diaria durante siete días antes de la exposición, una dosis al día y una dosis diaria durante siete días después de la última exposición. La figura 1 muestra cronologías día a día con iconos de comprimidos: para las personas idóneas para la PrEP a demanda (ED-PrEP), una dosis doble y luego dosis diarias hasta dos días después de la relación sexual (dentro o más allá de las 24 horas siguientes a la dosis inicial); para las no idóneas, siete dosis diarias antes de la exposición, dosis diarias continuas y siete dosis diarias tras la última exposición.",
        "fr": "Rendu de page comprenant la fin du tableau 1 et la figure 1. Le tableau indique la posologie de la PrEP orale par population : les hommes cisgenres et les personnes trans et de genre divers assignées au sexe masculin à la naissance ayant une exposition sexuelle et ne prenant pas d’hormones exogènes à base d’estradiol prennent une double dose 2 à 24 heures avant l’exposition, une dose par jour, et une dose par jour jusqu’à deux jours après la dernière exposition ; les autres populations (dont les femmes cisgenres, les personnes prenant des hormones à base d’estradiol et les personnes utilisant la PrEP pour prévenir l’acquisition du VIH liée aux pratiques d’injection) prennent une dose quotidienne pendant sept jours avant l’exposition, une dose par jour, et une dose quotidienne pendant sept jours après la dernière exposition. La figure 1 présente des chronologies jour par jour avec des icônes de comprimés : pour les personnes éligibles à la PrEP à la demande (ED-PrEP), une double dose puis des doses quotidiennes jusqu’à deux jours après le rapport (dans les 24 heures suivant la dose initiale ou au-delà) ; pour les personnes non éligibles, sept doses quotidiennes avant l’exposition, la poursuite des doses quotidiennes et sept doses quotidiennes après la dernière exposition.",
        "ru": "Изображение страницы с окончанием таблицы 1 и рисунком 1. В таблице приведена схема приема пероральной ДКП по группам населения: цисгендерные мужчины и трансгендерные и гендерно разнообразные люди, которым при рождении был приписан мужской пол, имеющие половые контакты и не принимающие экзогенные гормоны на основе эстрадиола, принимают двойную дозу за 2–24 часа до контакта, затем одну дозу в день и одну дозу в день до двух дней после последнего контакта; другие группы (включая цисгендерных женщин, людей, принимающих гормоны на основе эстрадиола, и людей, использующих ДКП для профилактики заражения ВИЧ при инъекционных практиках) принимают одну дозу ежедневно в течение семи дней до контакта, затем одну дозу в день и одну дозу ежедневно в течение семи дней после последнего контакта. На рисунке 1 показаны пошаговые графики по дням со значками таблеток: для лиц, которым подходит ДКП по требованию (ED-PrEP), — двойная доза, затем ежедневные дозы до двух дней после полового контакта (в пределах 24 часов после первой дозы или позже); для остальных — семь ежедневных доз до контакта, продолжение ежедневного приема и семь ежедневных доз после последнего контакта."
      },
      "state": "draft"
    },
    {
      "id": "img-p028-1",
      "file": "images/img-p028-1.webp",
      "page": 28,
      "narratives": {
        "en": "Photograph (Fig. 2) of a white van in Dong Nai province, Viet Nam, wrapped in blue PrEP branding with two young men and the slogans 'I ♥ PrEP BUS', 'PrEP in our hands' and 'PrEP trong tầm tay', with bubbles reading 'PrEP' and 'ED-PrEP'.",
        "ar": "صورة (الشكل 2) لشاحنة بيضاء في مقاطعة دونغ ناي بفييت نام، مغلفة بتصميم أزرق خاص بالوقاية قبل التعرض (PrEP) يُظهر شابين وشعارات «I ♥ PrEP BUS» و«PrEP in our hands» و«PrEP trong tầm tay»، مع فقاعات مكتوب عليها «PrEP» و«ED-PrEP».",
        "zh": "照片（图2）：越南同奈省的一辆白色面包车，车身贴有蓝色暴露前预防（PrEP）宣传图案，画有两名年轻男子以及“I ♥ PrEP BUS”“PrEP in our hands”和“PrEP trong tầm tay”标语，气泡中写有“PrEP”和“ED-PrEP”。",
        "es": "Fotografía (fig. 2) de una furgoneta blanca en la provincia de Dong Nai (Viet Nam), rotulada en azul con publicidad sobre la PrEP, en la que aparecen dos hombres jóvenes y los lemas «I ♥ PrEP BUS», «PrEP in our hands» y «PrEP trong tầm tay», con burbujas que dicen «PrEP» y «ED-PrEP».",
        "fr": "Photographie (fig. 2) d’une camionnette blanche dans la province de Dong Nai (Viet Nam), habillée d’un visuel bleu sur la PrEP montrant deux jeunes hommes et les slogans « I ♥ PrEP BUS », « PrEP in our hands » et « PrEP trong tầm tay », avec des bulles indiquant « PrEP » et « ED-PrEP ».",
        "ru": "Фотография (рис. 2): белый микроавтобус в провинции Донгнай (Вьетнам), оклеенный синей рекламой ДКП (PrEP) с изображением двух молодых людей и лозунгами «I ♥ PrEP BUS», «PrEP in our hands» и «PrEP trong tầm tay», а также пузырями с надписями «PrEP» и «ED-PrEP»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p028",
      "file": "figures/vfig-p028.webp",
      "page": 28,
      "shows": [
        "Box 8",
        "Figure 2"
      ],
      "narratives": {
        "en": "Render of Box 8, 'Bringing PrEP closer to home in Viet Nam', with its text on mobile PrEP and STI services and Fig. 2, a photograph of the blue-branded 'I ♥ PrEP BUS' van of the PrEP on Wheels programme in Dong Nai province (photo credit: PATH).",
        "ar": "عرض للإطار 8، «تقريب الوقاية قبل التعرض من المنازل في فييت نام»، مع نصه عن الخدمات المتنقلة للوقاية قبل التعرض والعدوى المنقولة جنسياً، والشكل 2، وهو صورة لشاحنة «I ♥ PrEP BUS» ذات التصميم الأزرق التابعة لبرنامج PrEP on Wheels في مقاطعة دونغ ناي (مصدر الصورة: PATH).",
        "zh": "专栏8“在越南让PrEP更贴近家门”的渲染图，包含关于流动PrEP和性传播感染服务的正文以及图2——同奈省“PrEP on Wheels”项目的蓝色“I ♥ PrEP BUS”宣传车照片（照片来源：PATH）。",
        "es": "Imagen del recuadro 8, «Acercar la PrEP al hogar en Viet Nam», con su texto sobre los servicios móviles de PrEP e ITS y la fig. 2, una fotografía de la furgoneta azul «I ♥ PrEP BUS» del programa PrEP on Wheels en la provincia de Dong Nai (crédito fotográfico: PATH).",
        "fr": "Rendu de l’encadré 8, « Rapprocher la PrEP du domicile au Viet Nam », avec son texte sur les services mobiles de PrEP et d’IST et la fig. 2, photographie de la camionnette bleue « I ♥ PrEP BUS » du programme PrEP on Wheels dans la province de Dong Nai (crédit photo : PATH).",
        "ru": "Изображение вставки 8 «Приближение ДКП к дому во Вьетнаме» с текстом о мобильных услугах ДКП и ИППП и рис. 2 — фотографией синего микроавтобуса «I ♥ PrEP BUS» программы PrEP on Wheels в провинции Донгнай (фото: PATH)."
      },
      "state": "draft"
    },
    {
      "id": "img-p030-1",
      "file": "images/img-p030-1.webp",
      "page": 30,
      "narratives": {
        "en": "Photograph (Fig. 3) of a young man seen from behind at a round table, holding a phone or test device, with an opened prevention kit including a pink pouch, packets and a small bottle in front of him, and a plant and glasses on the table.",
        "ar": "صورة (الشكل 3) لشاب يُرى من الخلف جالساً إلى طاولة مستديرة ويحمل هاتفاً أو جهاز اختبار، وأمامه مجموعة وقاية مفتوحة تضم حقيبة وردية وأكياساً وزجاجة صغيرة، مع نبتة ونظارة على الطاولة.",
        "zh": "照片（图3）：一名年轻男子背对镜头坐在圆桌前，手持手机或检测装置，面前放着一个已打开的预防包，内有粉色小袋、若干小包和一个小瓶，桌上还有一盆植物和一副眼镜。",
        "es": "Fotografía (fig. 3) de un hombre joven visto de espaldas ante una mesa redonda, que sostiene un teléfono o un dispositivo de prueba, con un kit de prevención abierto delante (una bolsa rosa, sobres y un frasco pequeño) y una planta y unas gafas sobre la mesa.",
        "fr": "Photographie (fig. 3) d’un jeune homme vu de dos à une table ronde, tenant un téléphone ou un dispositif de test, avec devant lui un kit de prévention ouvert comprenant une pochette rose, des sachets et un petit flacon, ainsi qu’une plante et des lunettes sur la table.",
        "ru": "Фотография (рис. 3): молодой человек, снятый со спины, сидит за круглым столом с телефоном или тестовым устройством в руках; перед ним открытый профилактический набор с розовым мешочком, пакетиками и небольшим флаконом, на столе также растение и очки."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p030",
      "file": "figures/vfig-p030.webp",
      "page": 30,
      "shows": [
        "Box 10",
        "Figure 3"
      ],
      "narratives": {
        "en": "Render of Box 10, 'Telehealth for PrEP during COVID-19 in Brazil', with its text on the ImPrEP and PrEP1519 projects and Fig. 3, a photograph of a PrEP1519 participant at home with an HIV prevention kit including an HIVST (photo credit: Project1519).",
        "ar": "عرض للإطار 10، «الرعاية الصحية عن بُعد للوقاية قبل التعرض أثناء جائحة كوفيد-19 في البرازيل»، مع نصه عن مشروعي ImPrEP وPrEP1519، والشكل 3، وهو صورة لمشارك في PrEP1519 في منزله مع مجموعة للوقاية من فيروس العوز المناعي البشري تتضمن اختباراً ذاتياً للفيروس (مصدر الصورة: Project1519).",
        "zh": "专栏10“巴西在COVID-19期间为PrEP提供远程医疗”的渲染图，包含关于ImPrEP和PrEP1519项目的正文以及图3——一名PrEP1519参与者在家中收到含艾滋病毒自我检测的艾滋病毒预防包的照片（照片来源：Project1519）。",
        "es": "Imagen del recuadro 10, «Telesalud para la PrEP durante la COVID-19 en el Brasil», con su texto sobre los proyectos ImPrEP y PrEP1519 y la fig. 3, una fotografía de un participante de PrEP1519 en su casa con un kit de prevención del VIH que incluye una autoprueba del VIH (crédito fotográfico: Project1519).",
        "fr": "Rendu de l’encadré 10, « Télésanté pour la PrEP pendant la COVID-19 au Brésil », avec son texte sur les projets ImPrEP et PrEP1519 et la fig. 3, photographie d’un participant de PrEP1519 à domicile avec un kit de prévention du VIH comprenant un autotest VIH (crédit photo : Project1519).",
        "ru": "Изображение вставки 10 «Телемедицина для ДКП во время COVID-19 в Бразилии» с текстом о проектах ImPrEP и PrEP1519 и рис. 3 — фотографией участника PrEP1519 дома с набором для профилактики ВИЧ, включающим самотест на ВИЧ (фото: Project1519)."
      },
      "state": "draft"
    },
    {
      "id": "img-p031-1",
      "file": "images/img-p031-1.webp",
      "page": 31,
      "narratives": {
        "en": "Photograph (Fig. 4) of the entrance of a small pharmacy in Kenya with a sign reading 'SANAA PHARMACEUTICALS' and vertical signs reading 'DUKA LA DAWA' and 'CHEMIST', with shelves of products and posters inside.",
        "ar": "صورة (الشكل 4) لمدخل صيدلية صغيرة في كينيا عليها لافتة «SANAA PHARMACEUTICALS» ولافتتان عموديتان «DUKA LA DAWA» و«CHEMIST»، مع رفوف منتجات وملصقات في الداخل.",
        "zh": "照片（图4）：肯尼亚一家小药店的入口，招牌上写着“SANAA PHARMACEUTICALS”，竖向招牌写着“DUKA LA DAWA”和“CHEMIST”，店内有货架和海报。",
        "es": "Fotografía (fig. 4) de la entrada de una pequeña farmacia en Kenya con un letrero que dice «SANAA PHARMACEUTICALS» y letreros verticales con «DUKA LA DAWA» y «CHEMIST», con estanterías de productos y carteles en el interior.",
        "fr": "Photographie (fig. 4) de l’entrée d’une petite pharmacie au Kenya, avec une enseigne « SANAA PHARMACEUTICALS » et des panneaux verticaux « DUKA LA DAWA » et « CHEMIST », des étagères de produits et des affiches à l’intérieur.",
        "ru": "Фотография (рис. 4): вход в небольшую аптеку в Кении с вывеской «SANAA PHARMACEUTICALS» и вертикальными вывесками «DUKA LA DAWA» и «CHEMIST»; внутри полки с товарами и плакаты."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p031",
      "file": "figures/vfig-p031.webp",
      "page": 31,
      "shows": [
        "Box 11",
        "Box 12",
        "Figure 4"
      ],
      "narratives": {
        "en": "Page render with the section 'PrEP delivery in pharmacies', Box 11 'Evidence about PrEP delivery in pharmacies', and Box 12 'Oral PrEP initiation and continuation in private pharmacies in Kenya', which includes Fig. 4, a photograph of the SANAA PHARMACEUTICALS shopfront (photo credit: Fred Hutch/Katrina Ortblad).",
        "ar": "عرض لصفحة يتضمن قسم «تقديم الوقاية قبل التعرض في الصيدليات»، والإطار 11 «بيّنات بشأن تقديم الوقاية قبل التعرض في الصيدليات»، والإطار 12 «بدء الوقاية الفموية قبل التعرض والاستمرار فيها في الصيدليات الخاصة في كينيا» الذي يتضمن الشكل 4، وهو صورة لواجهة صيدلية SANAA PHARMACEUTICALS (مصدر الصورة: Fred Hutch/Katrina Ortblad).",
        "zh": "页面渲染图，包含“在药房提供PrEP”一节、专栏11“关于在药房提供PrEP的证据”以及专栏12“肯尼亚私营药房启动和持续口服PrEP”，其中包括图4——SANAA PHARMACEUTICALS药店门面照片（照片来源：Fred Hutch/Katrina Ortblad）。",
        "es": "Imagen de página con la sección «Dispensación de la PrEP en farmacias», el recuadro 11 «Evidencia sobre la dispensación de la PrEP en farmacias» y el recuadro 12 «Inicio y continuación de la PrEP oral en farmacias privadas de Kenya», que incluye la fig. 4, una fotografía de la fachada de SANAA PHARMACEUTICALS (crédito fotográfico: Fred Hutch/Katrina Ortblad).",
        "fr": "Rendu de page comprenant la section « Délivrance de la PrEP en pharmacie », l’encadré 11 « Données sur la délivrance de la PrEP en pharmacie » et l’encadré 12 « Initiation et poursuite de la PrEP orale dans les pharmacies privées au Kenya », qui inclut la fig. 4, photographie de la devanture de SANAA PHARMACEUTICALS (crédit photo : Fred Hutch/Katrina Ortblad).",
        "ru": "Изображение страницы с разделом «Предоставление ДКП в аптеках», вставкой 11 «Данные о предоставлении ДКП в аптеках» и вставкой 12 «Начало и продолжение пероральной ДКП в частных аптеках Кении», включающей рис. 4 — фотографию входа в аптеку SANAA PHARMACEUTICALS (фото: Fred Hutch/Katrina Ortblad)."
      },
      "state": "draft"
    },
    {
      "id": "img-p046-1",
      "file": "images/img-p046-1.webp",
      "page": 46,
      "narratives": {
        "en": "ISBN barcode for 9789240053694.",
        "ar": "الرمز الشريطي للرقم الدولي المعياري للكتاب (ISBN) 9789240053694.",
        "zh": "国际标准书号（ISBN）条形码9789240053694。",
        "es": "Código de barras del ISBN 9789240053694.",
        "fr": "Code-barres ISBN 9789240053694.",
        "ru": "Штрихкод ISBN 9789240053694."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Starting, using and stopping TDF-based oral PrEP safely",
      "pages": [
        13
      ],
      "columns": [
        {
          "titles": "Population"
        },
        {
          "titles": "Starting oral PrEP"
        },
        {
          "titles": "Using oral PrEP"
        },
        {
          "titles": "Stopping oral PrEP"
        }
      ],
      "rows": [
        [
          "Cisgender men and trans and gender diverse people assigned male at birtha who: • have sexual exposure AND • are not taking exogenous estradiol-based hormones",
          "Take a double dose 2–24 hours before potential sexual exposure (ideally closer to 24 hours before potential exposure)",
          "Take one dose per day",
          "Take one dose per day until two days after the day of the last potential sexual exposure"
        ],
        [
          "Cisgender women and trans and gender diverse people assigned female at birtha Cisgender men and trans and gender diverse people assigned male at birtha who are taking exogenous estradiol-based hormones People using oral PrEP to prevent HIV acquisition from injecting practices",
          "Take one dose daily for seven days before potential exposure",
          "Take one dose per day",
          "Take one dose daily for seven days after last potential exposure"
        ]
      ],
      "notes": "PrEP: pre-exposure prophylaxis; TDF: tenofovir disoproxil fumarate. a “Trans and gender diverse people” is an umbrella term for those whose gender identity, roles and expression does not conform to the norms and expectations traditionally associated with the sex assigned to them at birth; it includes people who are transsexual, transgender, or otherwise gender nonconforming or gender incongruent. Transgender people may self-identify as transgender, female, male, transwoman or transman, trans-sexual or one of many other gender nonconforming identities. [Row 2 groups three populations (printed as separate paragraphs in one cell) that share the same regimen.]",
      "narratives": {
        "en": "How to start, use and stop TDF-based oral PrEP for two groups: people assigned male at birth with sexual exposure who are not taking estradiol-based hormones (eligible for a double starting dose), and all other populations, including people assigned female at birth, those taking estradiol-based hormones and people who inject drugs (seven-day lead-in and stopping periods).",
        "ar": "كيفية بدء العلاج الوقائي قبل التعرض الفموي القائم على TDF واستخدامه وإيقافه لمجموعتين: الأشخاص المحدد جنسهم عند الولادة ذكوراً المعرضون جنسياً ولا يتناولون هرمونات قائمة على الإستراديول (يحق لهم بدء العلاج بجرعة مضاعفة)، وسائر الفئات الأخرى، بمن فيها الأشخاص المحدد جنسهم عند الولادة إناثاً ومن يتناولون هرمونات الإستراديول ومتعاطو المخدرات بالحقن (فترة بدء وإيقاف مدتها سبعة أيام).",
        "zh": "针对两类人群说明如何开始、使用和停止以TDF为基础的口服暴露前预防：出生时被指定为男性、有性暴露且未服用雌二醇类激素者（可采用双倍起始剂量），以及所有其他人群，包括出生时被指定为女性者、服用雌二醇类激素者和注射吸毒者（开始前和停止后各需七天）。",
        "es": "Cómo iniciar, usar y suspender la PrEP oral basada en TDF para dos grupos: personas a las que se asignó el sexo masculino al nacer con exposición sexual que no toman hormonas a base de estradiol (aptas para una dosis doble inicial) y todas las demás poblaciones, incluidas las personas a las que se asignó el sexo femenino al nacer, las que toman hormonas a base de estradiol y las personas que se inyectan drogas (siete días antes y después).",
        "fr": "Comment commencer, utiliser et arrêter la PrEP orale à base de TDF pour deux groupes : les personnes de sexe masculin assigné à la naissance ayant une exposition sexuelle et ne prenant pas d’hormones à base d’estradiol (éligibles à une double dose initiale), et toutes les autres populations, y compris les personnes de sexe féminin assigné à la naissance, celles prenant des hormones à base d’estradiol et les personnes qui s’injectent des drogues (sept jours avant et après).",
        "ru": "Порядок начала, применения и прекращения пероральной ДКП на основе TDF для двух групп: лиц, которым при рождении был присвоен мужской пол, имеющих половой контакт и не принимающих препараты на основе эстрадиола (может применяться двойная начальная доза), и всех остальных групп, включая лиц, которым при рождении был присвоен женский пол, принимающих эстрадиол и потребителей инъекционных наркотиков (по семь дней до и после)."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2. Suggested procedures for measuring kidney function for TDF-containing oral PrEP",
      "pages": [
        19
      ],
      "columns": [
        {
          "titles": "Population"
        },
        {
          "titles": "At initiation",
          "group": "Measurement of kidney function:"
        },
        {
          "titles": "At follow-up",
          "group": "Measurement of kidney function:"
        }
      ],
      "rows": [
        [
          "Individuals aged under 30 years and no kidney-related comorbiditiesa",
          "Optional",
          "If no initiation test conducted or if initiation test is normal,b follow-up is optional If initiation test result suggests at least mild loss of kidney function,c follow-up measurements every 6–12 months are suggested"
        ],
        [
          "Individuals aged 30–49 years and no kidney-related comorbiditiesa",
          "Optional/conduct once, at or within 1–3 months of initiationd",
          "If initiation test is normal,b follow-up is optional If initiation test result suggests at least mild loss of kidney function,c follow-up measurements every 6–12 months are suggested"
        ],
        [
          "Individuals aged 50+ years and no kidney-related comorbiditiesa Individuals of any age with kidney-related comorbiditiesa Individuals with previous measurement of kidney function suggesting at least mild loss of kidney functionc",
          "Conduct once, at or within 1–3 months of initiation",
          "Follow-up measurements every 6–12 months"
        ]
      ],
      "notes": "eGFR: estimated glomerular filtration rate; PrEP: pre-exposure prophylaxis; TDF: tenofovir disoproxil fumarate. a Kidney-related comorbidities include chronic kidney disease or risk factors such as diabetes or hypertension. There may be an increased risk of kidney-related adverse events during pregnancy, and conditions such as preeclampsia may cause kidney impairment, so more frequent kidney function testing may be considered during pregnancy. b eGFR ≥90 mL/min per 1.73 m2 or creatinine clearance of ≥90 mL/min. c eGFR <90 mL/min per 1.73 m2 or creatinine clearance of <90 mL/min. d Risks of kidney impairment and kidney-related adverse events remain low among those aged 30–49 years without kidney-related comorbidities, particularly those aged 30–39, so kidney function monitoring can be considered optional in this group, too, depending on available resources.",
      "narratives": {
        "en": "Suggested kidney function testing at PrEP initiation and at follow-up for people taking TDF-containing oral PrEP, by population group defined by age (under 30, 30–49, 50+), kidney-related comorbidities and previous evidence of reduced kidney function.",
        "ar": "الإجراءات المقترحة لفحص وظائف الكلى عند بدء العلاج الوقائي قبل التعرض وخلال المتابعة لمن يتناولون العلاج الفموي المحتوي على TDF، بحسب الفئة السكانية المحددة بالعمر (دون 30، و30–49، و50 فأكثر) والأمراض المصاحبة المتعلقة بالكلى والأدلة السابقة على تراجع وظائف الكلى.",
        "zh": "针对服用含TDF口服暴露前预防药物者，按年龄（30岁以下、30–49岁、50岁及以上）、肾脏相关合并症及既往肾功能下降证据划分人群，建议在开始用药时和随访时进行的肾功能检测。",
        "es": "Pruebas de función renal sugeridas al inicio de la PrEP y durante el seguimiento en personas que toman PrEP oral con TDF, por grupo de población según la edad (menos de 30, 30-49, 50 o más), las comorbilidades renales y los antecedentes de disminución de la función renal.",
        "fr": "Examens de la fonction rénale suggérés à l’instauration de la PrEP et pendant le suivi chez les personnes prenant une PrEP orale contenant du TDF, par groupe de population défini selon l’âge (moins de 30 ans, 30-49 ans, 50 ans et plus), les comorbidités rénales et des antécédents de diminution de la fonction rénale.",
        "ru": "Рекомендуемое исследование функции почек при начале ДКП и в ходе последующего наблюдения у лиц, принимающих пероральную ДКП с TDF, по группам населения в зависимости от возраста (до 30, 30–49, 50+ лет), сопутствующих заболеваний почек и ранее выявленного снижения функции почек."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3. The building blocks of differentiated PrEP service delivery",
      "pages": [
        25
      ],
      "columns": [
        {
          "titles": "Building block"
        },
        {
          "titles": "Initiation",
          "group": "PrEP initiation, initial follow-up (0–3 months), and re-initiation"
        },
        {
          "titles": "Initial follow-up (0–3 months) (if required)",
          "group": "PrEP initiation, initial follow-up (0–3 months), and re-initiation"
        },
        {
          "titles": "Re-initiation after discontinuation",
          "group": "PrEP initiation, initial follow-up (0–3 months), and re-initiation"
        },
        {
          "titles": "PrEP refill",
          "group": "PrEP continuation (3+ months)"
        },
        {
          "titles": "Follow-up",
          "group": "PrEP continuation (3+ months)"
        }
      ],
      "rows": [
        [
          "Where? Service location (e.g., primary health care facility, community setting, virtual setting)",
          "Locations for PrEP assessment and initiation",
          "Locations for initial follow-up",
          "Locations for PrEP re-initiation",
          "Locations where PrEP refills can be collected",
          "Locations where follow-up services will be provided"
        ],
        [
          "Who? Service provider (e.g., physician, nurse, pharmacist, peer)",
          "Service provider/s authorized to assess for and initiate PrEP",
          "Service providers who can carry out initial follow-up visit/s",
          "Service provider/s authorized to re-initiate PrEP",
          "Service provider/s who can dispense PrEP refills",
          "Service provider/s who conduct follow-up"
        ],
        [
          "When? Service frequency (e.g., monthly, every 3 months)",
          "Timing of PrEP assessment and initiation",
          "Timing of initial follow-up",
          "Timing of PrEP re-initiation",
          "Frequency of PrEP refill visits (length of supply)",
          "Frequency of follow-up services"
        ],
        [
          "What? Service package (including HIV testing, clinical monitoring, PrEP prescription and dispensing, and comprehensive services)",
          "Service package for PrEP assessment and initiation",
          "Service package at initial follow-up",
          "Service package for PrEP re-initiation",
          "Service package with PrEP refill",
          "Service package with follow-up"
        ]
      ],
      "notes": "PrEP: pre-exposure prophylaxis. Source: Adapted from the International AIDS Society framework for differentiated service delivery (61).",
      "narratives": {
        "en": "Framework for differentiated PrEP service delivery: for each building block (where, who, when, what), the table names what has to be defined at initiation, initial follow-up and re-initiation, and during continuation (PrEP refills and follow-up).",
        "ar": "إطار لتقديم خدمات متمايزة للعلاج الوقائي قبل التعرض: لكل لبنة أساسية (أين، ومن، ومتى، وماذا) يحدد الجدول ما ينبغي تحديده عند البدء والمتابعة الأولية وإعادة البدء، وخلال الاستمرار (إعادة صرف الدواء والمتابعة).",
        "zh": "差异化暴露前预防服务提供框架：针对每个基本要素（在哪里、由谁、何时、提供什么），该表列出在开始用药、初始随访和重新开始阶段以及持续用药阶段（续药和随访）需要确定的内容。",
        "es": "Marco para la prestación diferenciada de servicios de PrEP: para cada componente básico (dónde, quién, cuándo, qué), el cuadro indica lo que debe definirse al inicio, en el seguimiento inicial y al reiniciar, y durante la continuación (reposición de la PrEP y seguimiento).",
        "fr": "Cadre de prestation différenciée des services de PrEP : pour chaque élément constitutif (où, qui, quand, quoi), le tableau indique ce qui doit être défini à l’instauration, lors du suivi initial et de la reprise, et pendant la poursuite (renouvellement de la PrEP et suivi).",
        "ru": "Схема дифференцированного предоставления услуг ДКП: для каждого структурного элемента (где, кто, когда, что) в таблице указано, что необходимо определить при начале, первичном наблюдении и возобновлении приема, а также на этапе продолжения (пополнение запаса ДКП и последующее наблюдение)."
      },
      "csv": "tables/table-3.csv"
    },
    {
      "label": "Table A2.1",
      "caption": "Table A2.1. Regional and country income level distribution of online survey participantsa,b",
      "pages": [
        43
      ],
      "columns": [
        {
          "titles": "WHO region"
        },
        {
          "titles": "LMIC",
          "group": "Countries represented by respondents (#)"
        },
        {
          "titles": "HIC",
          "group": "Countries represented by respondents (#)"
        },
        {
          "titles": "LMIC",
          "group": "Respondents from regions (#)"
        },
        {
          "titles": "HIC",
          "group": "Respondents from regions (#)"
        },
        {
          "titles": "LMIC",
          "group": "Proportion of survey respondents from regions"
        },
        {
          "titles": "HIC",
          "group": "Proportion of survey respondents from regions"
        }
      ],
      "rows": [
        [
          "Africa",
          "27",
          "–",
          "805",
          "–",
          "59.5%",
          "–"
        ],
        [
          "Americas",
          "14",
          "5",
          "50",
          "52",
          "3.7%",
          "3.8%"
        ],
        [
          "Eastern Mediterranean",
          "4",
          "–",
          "4",
          "–",
          "0.3%",
          "–"
        ],
        [
          "Europe",
          "6",
          "13",
          "10",
          "273",
          "0.7%",
          "20.2%"
        ],
        [
          "South-East Asia",
          "8",
          "–",
          "54",
          "–",
          "4.0%",
          "–"
        ],
        [
          "Western Pacific",
          "5",
          "2",
          "69",
          "36",
          "5.1%",
          "2.7%"
        ],
        [
          "TOTAL",
          "64",
          "20",
          "992",
          "361",
          "73.3%",
          "26.7%"
        ]
      ],
      "notes": "HIC: high-income country; LMIC: low- and middle-income country. a Country income level data source: https://data.worldbank.org/ [The caption carries a footnote mark \"b\" but no footnote b is printed on the page.]",
      "narratives": {
        "en": "Distribution of online survey participants in the global PrEP provider study by WHO region and country income level (LMIC vs HIC): number of countries represented, number of respondents, and proportion of all respondents.",
        "ar": "توزيع المشاركين في المسح الإلكتروني ضمن الدراسة العالمية لمقدمي العلاج الوقائي قبل التعرض بحسب إقليم المنظمة ومستوى دخل البلد (البلدان المنخفضة والمتوسطة الدخل مقابل المرتفعة الدخل): عدد البلدان الممثلة وعدد المجيبين ونسبتهم من مجموع المجيبين.",
        "zh": "全球暴露前预防服务提供者研究在线调查参与者按世卫组织区域和国家收入水平（中低收入与高收入国家）的分布：所代表的国家数、受访者人数及占全部受访者的比例。",
        "es": "Distribución de los participantes en la encuesta en línea del estudio mundial sobre proveedores de PrEP por región de la OMS y nivel de ingresos del país (PIBM frente a PIA): número de países representados, número de encuestados y proporción del total de encuestados.",
        "fr": "Répartition des participants à l’enquête en ligne de l’étude mondiale sur les prestataires de PrEP par Région de l’OMS et niveau de revenu du pays (PRFI/PRE) : nombre de pays représentés, nombre de répondants et proportion de l’ensemble des répondants.",
        "ru": "Распределение участников онлайн-опроса в рамках глобального исследования поставщиков услуг ДКП по регионам ВОЗ и уровню дохода стран (СНСД и СВД): число представленных стран, число респондентов и их доля от общего числа респондентов."
      },
      "csv": "tables/table-a2-1.csv"
    },
    {
      "label": "Table A2.2",
      "caption": "Table A2.2. Geographic representation of participants in in-depth interviews on PrEP provider perspectives",
      "pages": [
        44
      ],
      "columns": [
        {
          "titles": "WHO region"
        },
        {
          "titles": "Number of participants"
        },
        {
          "titles": "Countries"
        }
      ],
      "rows": [
        [
          "Africa",
          "7",
          "Mali, Namibia, Nigeria, Uganda (2), Zambia, Zimbabwe"
        ],
        [
          "Americas",
          "8",
          "Brazil, Dominican Republic, Guatemala, Mexico, USA (4)"
        ],
        [
          "Eastern Mediterranean",
          "1",
          "Lebanon"
        ],
        [
          "Europe",
          "6",
          "Poland, Spain, Switzerland, United Kingdom, Ukraine (2)"
        ],
        [
          "South-East Asia",
          "5",
          "Indonesia, Myanmar, Nepal, Sri Lanka, Thailand"
        ],
        [
          "Western Pacific",
          "3",
          "Australia (2), Thailand"
        ]
      ],
      "notes": "PrEP: pre-exposure prophylaxis. Numbers refer to multiple PrEP providers who participated for listed countries.",
      "narratives": {
        "en": "Number of PrEP providers interviewed in depth in each WHO region and the countries they came from.",
        "ar": "عدد مقدمي خدمات العلاج الوقائي قبل التعرض الذين أُجريت معهم مقابلات متعمقة في كل إقليم من أقاليم المنظمة، والبلدان التي ينتمون إليها.",
        "zh": "各世卫组织区域接受深入访谈的暴露前预防服务提供者人数及其所在国家。",
        "es": "Número de proveedores de PrEP entrevistados en profundidad en cada región de la OMS y países de procedencia.",
        "fr": "Nombre de prestataires de PrEP interrogés en entretien approfondi dans chaque Région de l’OMS et pays dont ils sont issus.",
        "ru": "Число поставщиков услуг ДКП, прошедших углубленное интервью, в каждом регионе ВОЗ и страны, которые они представляют."
      },
      "csv": "tables/table-a2-2.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 34,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 35,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 14
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 5
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p36); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p7); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 33,
      "note": "33 of 35 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-360861"
  }
}
